



Proteomics International

LABORATORIES LTD

ASX/Media Release

6 April 2018

ASX code: PIQ

PIQ Options exercise update: Conversion of 90% of PIQO Options raises over \$3 million

- **PIQ options exercise will raise the maximum available amount of \$3.4 million**
- **PIQ option holders convert 90% of available options raising \$3.1 million**
- **Underwriters Alto Capital will take the shortfall of \$341,808**
- **Directors exercise over \$1 million of PIQO options**

Medical technology company Proteomics International Laboratories Ltd (Proteomics International, ASX: PIQ) is pleased to announce that a total of \$3.1 million of PIQO options (PIQO) have been exercised by option holders. This represents an uptake of 90% of the 17,231,856 options on issue at 31 December 2017.

The remaining PIQO options, representing a shortfall of \$341,808, are to be exercised by the underwriter, Alto Capital. The options expired on 31 March 2018 and on completion the exercise will raise the maximum available amount of \$3.4 million before costs.

The Board of Proteomics International exercised a total of \$1,051,484, comprising Managing Director Dr Richard Lipscombe \$551,484 (including \$255,000 cash and \$296,484 conversion of company loans), Chairman Terry Sweet \$250,000, and non-executive Directors Dr John Dunlop \$75,000, Roger Moore \$75,000, and Paul House \$75,000.

Managing Director, Dr Lipscombe, said "We are extremely pleased to have 90% of PIQO options exercised by option holders, including over \$1 million exercised by Directors of Proteomics International. We take this opportunity to thank the option holders for their overwhelming support. Proteomics International is now well positioned to drive the growth of its business and the commercialisation of PromarkerD, and to advance its strategic initiatives."

Pursuant to the underwriting agreement previously announced to the ASX on 14 March 2018, the underwriter has been notified of the unexercised PIQO options and the Company expects to issue shortfall shares to the underwriter in accordance with Listing Rule 7.2 (exception 12) by 16 April 2018.

ENDS

For further information please contact:

Dr Richard Lipscombe
Managing Director
Proteomics International Laboratories Ltd
T: +61 8 9389 1992
E: enquiries@proteomicsinternational.com
www.proteomicsinternational.com

Paul Hart [Investor Relations]
Director
Canary Capital
T: +61 421 051 474
E: phart@canarycapital.com.au

Proteomics International Laboratories Ltd

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: enquiries@proteomicsinternational.com | W: www.proteomicsinternational.com

Susan Fitzpatrick-Napier [Media Contact]
Digital Mantra Group
T: +61 2 8218 2144
E: team@dmgpr.com

About Proteomics International Laboratories (PILL) (www.proteomicsinternational.com)

PILL (ASX: PIQ) is a medical technology company at the forefront of predictive diagnostics and bio-analytical services. The company specialises in the area of proteomics – the industrial scale study of the structure and function of proteins. It received the world’s first ISO 17025 laboratory accreditation for proteomics services, and operates from state-of-the art facilities located on the QEII Medical Campus in Perth, Western Australia. The Company’s business model uses its proprietary technology platform across three integrated areas of diagnostics, drug discovery and analytical services.